By Prof. Khalil Al-salem
The following article is a summary for the most important updates on the journal of ophthamology in september 2024.
1- Delayed Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death
Study Purpose
The study aimed to determine whether delays between the diagnosis and treatment of posterior uveal melanoma are associated with an increased risk of metastatic death.
Study Design
Type: Retrospective, single-center cohort study.
Participants: 1,145 patients diagnosed with posterior uveal melanoma at St. Erik Eye Hospital, Stockholm, Sweden, between 2012 and 2022.
Key Findings
- Delays in Treatment:
The mean interval between diagnosis and treatment was 34 days.
A delay in treatment was linked to increased uveal melanoma (UM) mortality, particularly in patients with larger tumors (AJCC stage II and III).
For every additional 10-day delay in treatment, the risk of metastatic death increased by 1%.
Tumor Characteristics:
Larger tumors were more likely to be treated promptly.
Delayed treatment was associated with higher UM mortality in advanced-stage tumors but had a less clear impact on early-stage tumors (stage I).
Impact on Survival:
The study challenges the prevailing theory that metastasis occurs early in UM progression and suggests that even small delays in treatment can significantly affect outcomes.
A spike in mortality was observed in patients with stage I tumors who experienced delayed treatment, indicating potential late-stage metastatic seeding.
Conclusions
The study concludes that increasing the time between diagnosis and treatment of UM correlates with a higher risk of metastatic death.
It emphasizes the importance of prompt treatment and suggests that current understanding of UM metastatic progression may need revision.
The findings recommend validation in independent cohorts.
Study Limitations
Treatment timing was not randomized, and there could be unaccounted variables affecting outcomes.
Some prognostic markers and genetic factors were not fully evaluated.
This study underscores the critical need for timely treatment in uveal melanoma to improve patient outcomes.
2- Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study
Great New for patients with X-Linked Retinitis Pigmentosa. A new promissing genetic therapy Cotoretigene, has a promising efficacy and safety. A gene therapy targeting RPGR-associated X-linked retinitis pigmentosa (XLRP). Conducted as a phase 2/3 trial (NCT03116113), 29 male patients were randomized into low-dose, high-dose, and control groups.
Key Findings:
Efficacy: The primary endpoint—improvement in microperimetry sensitivity—was not met. However, significant improvements in low-luminance visual acuity (LLVA) and mean microperimetry sensitivity were observed in the low-dose group compared to controls.
Safety: The low-dose group had fewer serious ocular adverse events compared to the high-dose group, where ocular inflammation was more frequent.
Conclusion:
The study suggests potential benefits of low-dose Cotoretigene Toliparvovec in improving visual function in XLRP patients, though the primary endpoint was not achieved. Further investigation is warranted to optimize dosing and evaluate long-term outcomes.
3- Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye
A Dexamethasone intracanalicular plug was used to treat aqueous-deficient dry eye, the plug assumingly release Dexamethasone for 30 days at a regular pace.
Key Points:
Objective: Evaluate the efficacy and safety of a dexamethasone insert compared to a sham treatment (collagen plug) in patients with significant dry eye.
Design: A randomized controlled trial with 75 patients, where one eye received the dexamethasone insert, and the other eye received the sham treatment.
Results:
Efficacy: Dexamethasone-treated eyes showed significant improvement in corneal and conjunctival staining at 4 and 6 weeks. There was a modest, non-significant reduction in dryness symptoms.
Safety: Increased intraocular pressure was observed more frequently in dexamethasone-treated eyes but was manageable with short-term medication.
Conclusion: The dexamethasone insert is a promising treatment for severe dry eye, offering both tear retention and anti-inflammatory benefits without the need for frequent eye drops.
